1. Medicines
  2. Ophthalmology
  3. ▼Beovu® (brolucizumab)

Prescribing information

 

What is ▼Beovu® (brolucizumab) used for?

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Beovu is indicated in adults for the treatment of neovascular (wet) AMD and visual impairment due to diabetic macular oedema (DMO).1,2

Beovu SmPC (GB)

white arrow
 

Beovu SmPC (NI)

white arrow
 

AMD, age-related macular degeneration.

References

  1. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics Great Britain. 
  2. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics Northern Ireland.

 

Rate this content: 
Average: 2.3 (3 votes)
UK | May 2023 | 285239
Ophthalmology
Product

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]